Keohane et al. [22] proposed tafamidis, a non-NSAID highly specific transthyretin stabilizer, to delay the neurologic disease progression in the early-stage of transthyretin V30M familial amyloid polyneuropathy. The gene discussed is TTR; the disease is nervous system disorder.